A little over a decade ago, in 2013, obesity got its formal diagnosis. While the medical definition tries to break free from the idea that excess weight is solely a personal willpower failure, the public perception is a whole different ballgame?as complex and layered as a blockbuster movie plot. Enter the GLP-1s, the heroes of the weight-loss world. Do these weight loss drugs have the ability to create long lasting change in patient?s lives? And is the price tag justified by the outcomes, or are we in for a disappointing ending? Amidst escalating prices, the mounting pressure on health insurers, employers, states and Medicare to cover these drugs has also intensified. Currently, a growing number of health systems are ending coverage for their employees. And flaws in the reimbursement model have not kept pace with the demand for these drugs. Can the healthcare industry come up with a more sustainable model to cover the costs and monitor efficacy and ultimately, curb the trajectory of obesity rates? The plot seems to always thicken when experts weigh in on GLP-1s!